Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Tetrahydrozoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.85 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.85 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrozoline SCHEMBL34760 | 0.92 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL29603648 | 0.92 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL30292036 | 0.92 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL23496614 | 0.91 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL25702 | 0.91 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL29393067 | 0.91 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL871337 | 0.91 | ADRA1A (0.97) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL1512892 | 0.90 | ADRA1A (0.81) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL9296922 | 0.89 | CYP2D6 (0.97) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL10930958 | 0.83 | CYP2D6 (0.83) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000023-B1 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | US GOV HEALTH & HUMAN SERV (US) | 2011-02-23 | — | — | EP | disclosed |
| US-6911478-B2 | Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040180863-A1 | Novel, nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | GOVT. OF THE USA, REP. BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVS., OFFICE OF TECH. TRANSFER | 2004-09-16 | — | — | US | disclosed |
| US-6750254-B2 | N2O2- FUNCTIONALITY IS BOUND DIRECT TO A CARBON ATOM; TREATING BIOLOGICAL DISORDERS HYPERTENSION, RESTENOSIS, IMPOTENCY, GENETIC DISORDERS OR INFECTIONS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-06-15 | — | — | US | disclosed |
| US-20030166619-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY OF DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2003-09-04 | — | — | US | disclosed |
| US-6511991-B2 | Treating an amines with acetamidating agents to formacetamidine derivatives of the amine-containing compounds and treating the acetamidine derivatives with nitric oxide gas to form an amidine-derived diazeniumdiolate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-28 | — | — | US | disclosed |
| US-20010025052-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | HRABIE JOSEPH A (US) | 2001-09-27 | — | — | US | disclosed |
| US-6232336-B1 | HYPOTENSIVE AGENTS; NEUROTRANSMISSION; CYTOTOXICITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-05-15 | — | — | US | disclosed |
| EP-1000023-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999001427-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166619-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | NOS2, NOS1, NOS3 | ADRA1A 1350/4885ADRA2A 1631/4885ADRA1D 1324/4885 |
| US-20040180863-A1 | Novel, nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | NOS2, NOS1, NOS3 | ADRA1A 1314/4885ADRA2A 1528/4885ADRA1D 1278/4885 |
| US-20010025052-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | NOS2, NOS1, NOS3 | ADRA1A 1324/4885ADRA2A 1587/4885ADRA1D 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.